1,443 results on '"Farinati, F."'
Search Results
2. Distinguishing features of autoimmune gastritis depending on previous H. pylori infection or positivity to anti-parietal cell antibodies: Results from the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO)
- Author
-
Lenti, M, Miceli, E, Lahner, E, Natalello, G, Massironi, S, Schiepatti, A, Zingone, F, Sciola, V, Rossi, R, Cannizzaro, R, De Giorgi, E, Gregorio, V, Fazzino, E, Gentile, A, Petrucci, C, Dilaghi, E, Pivetta, G, Vanoli, A, Luinetti, O, Paulli, M, Anderloni, A, Vecchi, M, Biagi, F, Repici, A, Savarino, E, Joudaki, S, Delliponti, M, Pasini, A, Facciotti, F, Farinati, F, D'Elios, M, Della Bella, C, Annibale, B, Klersy, C, Corazza, G, Di Sabatino, A, Lenti M. V., Miceli E., Lahner E., Natalello G., Massironi S., Schiepatti A., Zingone F., Sciola V., Rossi R. E., Cannizzaro R., De Giorgi E. M., Gregorio V., Fazzino E., Gentile A., Petrucci C., Dilaghi E., Pivetta G., Vanoli A., Luinetti O., Paulli M., Anderloni A., Vecchi M., Biagi F., Repici A., Savarino E. V., Joudaki S., Delliponti M., Pasini A., Facciotti F., Farinati F., D'Elios M. M., Della Bella C., Annibale B., Klersy C., Corazza G. R., Di Sabatino A., Lenti, M, Miceli, E, Lahner, E, Natalello, G, Massironi, S, Schiepatti, A, Zingone, F, Sciola, V, Rossi, R, Cannizzaro, R, De Giorgi, E, Gregorio, V, Fazzino, E, Gentile, A, Petrucci, C, Dilaghi, E, Pivetta, G, Vanoli, A, Luinetti, O, Paulli, M, Anderloni, A, Vecchi, M, Biagi, F, Repici, A, Savarino, E, Joudaki, S, Delliponti, M, Pasini, A, Facciotti, F, Farinati, F, D'Elios, M, Della Bella, C, Annibale, B, Klersy, C, Corazza, G, Di Sabatino, A, Lenti M. V., Miceli E., Lahner E., Natalello G., Massironi S., Schiepatti A., Zingone F., Sciola V., Rossi R. E., Cannizzaro R., De Giorgi E. M., Gregorio V., Fazzino E., Gentile A., Petrucci C., Dilaghi E., Pivetta G., Vanoli A., Luinetti O., Paulli M., Anderloni A., Vecchi M., Biagi F., Repici A., Savarino E. V., Joudaki S., Delliponti M., Pasini A., Facciotti F., Farinati F., D'Elios M. M., Della Bella C., Annibale B., Klersy C., Corazza G. R., and Di Sabatino A.
- Abstract
Objectives:To describe the clinical features and the risk of developing gastric tumors in patients with autoimmune gastritis (AIG).Methods:This was a retrospective, longitudinal, multicenter study conducted at eight Italian tertiary referral centers. We retrieved clinical data from all histologically proven AIG patients. Differences between H. pylori-exposed vs H. pylori-naïve, and anti-parietal cell antibody (PCA)-positive vs PCA-negative patients were investigated. The rate of gastric adenocarcinoma and type 1 gastric neuroendocrine neoplasm (gNEN) was assessed. A multivariable model for factors associated to gNEN was fitted.Results:1598 patients with AIG (median age 58 years, IQR 46-68; F:M ratio 2.7:1) were included. H. pylori-naïve patients were more likely to have a first-degree family history of AIG (14.7% vs 8.9%; p=0.012), type 1 diabetes mellitus (4.9% vs 2.3%; p=0.025), and pernicious anemia (30.9% vs 21.1%; p=0.003). PCA-positive patients had significantly more associated autoimmune diseases (59.0% vs 42.9%; p<0.001) and were more likely to have been diagnosed by a case-finding strategy (15.3% vs 2.6%; p<0.001). Overall, 15 cases (0.9%) of gastric adenocarcinoma and 153 cases (9.6%) of gNEN occurred, with a global rate of 0.12 (95% CI 0.07-0.20) and 1.22 (95% CI 1.03-1.42) per 100 person/year, respectively. Having a vitamin B12/iron deficiency manifestation at AIG diagnosis was associated with an 16.44 (95% CI 9.94-27.20 p<0.001) hazard ratio of gNEN.Conclusions:The "pure"AIG pattern has typical features of an autoimmune disease and seems to be unrelated to H. pylori. In a tertiary referral setting, the risk of developing overt gastric adenocarcinoma is low, while patients with vitamin B12 deficiency complications at onset may benefit from a more intense endoscopic follow-up for early gNEN detection.
- Published
- 2024
3. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
- Author
-
Vitale, A, Cabibbo, G, Iavarone, M, Vigano, L, Pinato, D, Ponziani, F, Lai, Q, Casadei-Gardini, A, Celsa, C, Galati, G, Gambato, M, Crocetti, L, Renzulli, M, Giannini, E, Farinati, F, Trevisani, F, Cillo, U, Baccarani, U, Brancaccio, G, Cozzolongo, R, Cucchetti, A, De Matthaeis, N, Di Sandro, S, Famularo, S, Finotti, M, Foschi, F, Ghinolfi, D, Guarracino, M, Gruttadauria, S, Guarino, M, Kostandini, A, Lenci, I, Levi Sandri, G, Manzia, T, Marasco, G, Masarone, M, Mazzarelli, C, Melandro, F, Miele, L, Morisco, F, Nicolini, D, Pagano, D, Pelizzaro, F, Pieri, G, Piscaglia, F, Plaz Torres, M, Pravisani, R, Rendina, M, Romano, F, Russo, F, Sacco, R, Sangiovanni, A, Sposito, C, Tortora, R, Tovoli, F, Vigano, M, Violi, P, Vitale A., Cabibbo G., Iavarone M., Vigano L., Pinato D. J., Ponziani F. R., Lai Q., Casadei-Gardini A., Celsa C., Galati G., Gambato M., Crocetti L., Renzulli M., Giannini E. G., Farinati F., Trevisani F., Cillo U., Baccarani U., Brancaccio G., Cozzolongo R., Cucchetti A., De Matthaeis N., Di Sandro S., Famularo S., Finotti M., Foschi F. G., Ghinolfi D., Guarracino M., Gruttadauria S., Guarino M., Kostandini A., Lenci I., Levi Sandri G. B., Manzia T. M., Marasco G., Masarone M., Mazzarelli C., Melandro F., Miele L., Morisco F., Nicolini D., Pagano D., Pelizzaro F., Pieri G., Piscaglia F., Plaz Torres M. C., Pravisani R., Rendina M., Romano F., Russo F. P., Sacco R., Sangiovanni A., Sposito C., Tortora R., Tovoli F., Vigano M., Violi P., Vitale, A, Cabibbo, G, Iavarone, M, Vigano, L, Pinato, D, Ponziani, F, Lai, Q, Casadei-Gardini, A, Celsa, C, Galati, G, Gambato, M, Crocetti, L, Renzulli, M, Giannini, E, Farinati, F, Trevisani, F, Cillo, U, Baccarani, U, Brancaccio, G, Cozzolongo, R, Cucchetti, A, De Matthaeis, N, Di Sandro, S, Famularo, S, Finotti, M, Foschi, F, Ghinolfi, D, Guarracino, M, Gruttadauria, S, Guarino, M, Kostandini, A, Lenci, I, Levi Sandri, G, Manzia, T, Marasco, G, Masarone, M, Mazzarelli, C, Melandro, F, Miele, L, Morisco, F, Nicolini, D, Pagano, D, Pelizzaro, F, Pieri, G, Piscaglia, F, Plaz Torres, M, Pravisani, R, Rendina, M, Romano, F, Russo, F, Sacco, R, Sangiovanni, A, Sposito, C, Tortora, R, Tovoli, F, Vigano, M, Violi, P, Vitale A., Cabibbo G., Iavarone M., Vigano L., Pinato D. J., Ponziani F. R., Lai Q., Casadei-Gardini A., Celsa C., Galati G., Gambato M., Crocetti L., Renzulli M., Giannini E. G., Farinati F., Trevisani F., Cillo U., Baccarani U., Brancaccio G., Cozzolongo R., Cucchetti A., De Matthaeis N., Di Sandro S., Famularo S., Finotti M., Foschi F. G., Ghinolfi D., Guarracino M., Gruttadauria S., Guarino M., Kostandini A., Lenci I., Levi Sandri G. B., Manzia T. M., Marasco G., Masarone M., Mazzarelli C., Melandro F., Miele L., Morisco F., Nicolini D., Pagano D., Pelizzaro F., Pieri G., Piscaglia F., Plaz Torres M. C., Pravisani R., Rendina M., Romano F., Russo F. P., Sacco R., Sangiovanni A., Sposito C., Tortora R., Tovoli F., Vigano M., and Violi P.
- Abstract
Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma have increased the complexity of patient management. A dynamic adaptation of the available staging-based algorithms is required to allow flexible therapeutic allocation. In particular, real-world hepatocellular carcinoma management increasingly relies on factors independent of oncological staging, including patients’ frailty, comorbid burden, critical tumour location, multiple liver functional parameters, and specific technical contraindications impacting the delivery of treatment and resource availability. In this Policy Review we critically appraise how treatment allocation strictly based on pretreatment staging features has shifted towards a more personalised treatment approach, in which expert tumour boards assume a central role. We propose an evidence-based framework for hepatocellular carcinoma treatment based on the novel concept of multiparametric therapeutic hierarchy, in which different therapeutic options are ordered according to their survival benefit (ie, from surgery to systemic therapy). Moreover, we introduce the concept of converse therapeutic hierarchy, in which therapies are ordered according to their conversion abilities or adjuvant abilities (ie, from systemic therapy to surgery).
- Published
- 2023
4. Impact of ISO score on oncological outcomes and survival in liver transplant candidates with hepatocellular carcinoma
- Author
-
Pinto, E., primary, Gambato, M., additional, Pelizzaro, F., additional, Battistella, S., additional, Catanzaro, E., additional, Echavarrìa, V., additional, Russo, F.P., additional, Farinati, F., additional, Burra, P., additional, Gringeri, E., additional, Vitale, A., additional, and Cillo, U., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Predictors of extrahepatic progression in patients with hepatocellular carcinoma receiving transarterial chemoembolization
- Author
-
Pinto, E., primary, Pelizzaro, F., additional, Vitale, A., additional, Sangiovanni, A., additional, Cabibbo, G., additional, Caturelli, E., additional, Svegliati-Baroni, G., additional, Masotto, A., additional, Trevisani, F., additional, Foschi, F.G., additional, Piscaglia, F., additional, Raimondo, G., additional, Giannini, E.G., additional, Azzaroli, F., additional, Marra, F., additional, Mega, A., additional, Vidili, G., additional, Brunetto, M.R., additional, Missale, G., additional, Gasbarrini, A., additional, Rapaccini, G.L., additional, Guarino, M., additional, Magalotti, D., additional, Sacco, R., additional, Nardone, G., additional, Marco, M. Di, additional, and Farinati, F., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery
- Author
-
Famularo, S., Donadon, M., Cipriani, F., Fazio, F., Ardito, Francesco, Iaria, M., Perri, P., Conci, S., Dominioni, T., Lai, Q., La Barba, G., Patauner, S., Molfino, S., Germani, P., Zimmitti, G., Pinotti, E., Zanello, M., Fumagalli, L., Ferrari, C., Romano, M., Delvecchio, A., Valsecchi, M. G., Antonucci, A., Piscaglia, F., Farinati, F., Kawaguchi, Y., Hasegawa, K., Memeo, R., Zanus, G., Griseri, G., Chiarelli, M., Jovine, E., Zago, M., Abu Hilal, M., Tarchi, P., Baiocchi, G. L., Frena, A., Ercolani, G., Rossi, M., Maestri, M., Ruzzenente, A., Grazi, G. L., Dalla Valle, R., Romano, F., Giuliante, Felice, Ferrero, A., Aldrighetti, L., Bernasconi, D. P., Torzilli, G., Ardito F. (ORCID:0000-0003-1596-2862), Giuliante F. (ORCID:0000-0001-9517-8220), Famularo, S., Donadon, M., Cipriani, F., Fazio, F., Ardito, Francesco, Iaria, M., Perri, P., Conci, S., Dominioni, T., Lai, Q., La Barba, G., Patauner, S., Molfino, S., Germani, P., Zimmitti, G., Pinotti, E., Zanello, M., Fumagalli, L., Ferrari, C., Romano, M., Delvecchio, A., Valsecchi, M. G., Antonucci, A., Piscaglia, F., Farinati, F., Kawaguchi, Y., Hasegawa, K., Memeo, R., Zanus, G., Griseri, G., Chiarelli, M., Jovine, E., Zago, M., Abu Hilal, M., Tarchi, P., Baiocchi, G. L., Frena, A., Ercolani, G., Rossi, M., Maestri, M., Ruzzenente, A., Grazi, G. L., Dalla Valle, R., Romano, F., Giuliante, Felice, Ferrero, A., Aldrighetti, L., Bernasconi, D. P., Torzilli, G., Ardito F. (ORCID:0000-0003-1596-2862), and Giuliante F. (ORCID:0000-0001-9517-8220)
- Abstract
Importance: Clear indications on how to select retreatments for recurrent hepatocellular carcinoma (HCC) are still lacking. Objective: To create a machine learning predictive model of survival after HCC recurrence to allocate patients to their best potential treatment. Design, Setting, and Participants: Real-life data were obtained from an Italian registry of hepatocellular carcinoma between January 2008 and December 2019 after a median (IQR) follow-up of 27 (12-51) months. External validation was made on data derived by another Italian cohort and a Japanese cohort. Patients who experienced a recurrent HCC after a first surgical approach were included. Patients were profiled, and factors predicting survival after recurrence under different treatments that acted also as treatment effect modifiers were assessed. The model was then fitted individually to identify the best potential treatment. Analysis took place between January and April 2021. Exposures: Patients were enrolled if treated by reoperative hepatectomy or thermoablation, chemoembolization, or sorafenib. Main Outcomes and Measures: Survival after recurrence was the end point. Results: A total of 701 patients with recurrent HCC were enrolled (mean [SD] age, 71 [9] years; 151 [21.5%] female). Of those, 293 patients (41.8%) received reoperative hepatectomy or thermoablation, 188 (26.8%) received sorafenib, and 220 (31.4%) received chemoembolization. Treatment, age, cirrhosis, number, size, and lobar localization of the recurrent nodules, extrahepatic spread, and time to recurrence were all treatment effect modifiers and survival after recurrence predictors. The area under the receiver operating characteristic curve of the predictive model was 78.5% (95% CI, 71.7%-85.3%) at 5 years after recurrence. According to the model, 611 patients (87.2%) would have benefited from reoperative hepatectomy or thermoablation, 37 (5.2%) from sorafenib, and 53 (7.6%) from chemoembolization in terms of potential survival after re
- Published
- 2023
7. Increased level of presepsin in patients with acutely decompensated cirrhosis predicts development of acute-on-chronic liver failure
- Author
-
Zanetto, A., primary, Mion, M.M., additional, Ferrarese, A., additional, Shalaby, S., additional, Germani, G., additional, Gambato, M., additional, Russo, F.P., additional, Farinati, F., additional, Basso, D., additional, Burra, P., additional, and Senzolo, M., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Predictors of extrahepatic recurrence after transarterial chemoembolization as first-line therapy for hepatocellular carcinoma
- Author
-
Pinto, E., primary, Pelizzaro, F., additional, Vitale, A., additional, Giannini, E.G., additional, Trevisani, F., additional, and Farinati, F., additional
- Published
- 2023
- Full Text
- View/download PDF
9. T.11.1 ASSESSMENT OF PHYSICAL FRAILTY IN HOSPITALIZED PATIENTS WITH CIRRHOSIS: PRELIMINARY RESULTS FROM AN ONGOING PROSPECTIVE STUDY
- Author
-
D'Arcangelo, F., primary, Zanetto, A., additional, Grasso, M., additional, Bucci, M., additional, Gambato, M., additional, Germani, G., additional, Russo, F.P., additional, Senzolo, M., additional, Farinati, F., additional, and Burra, P., additional
- Published
- 2023
- Full Text
- View/download PDF
10. Preoperative predictors of recurrence beyond Milan criteria in hepatocellular carcinoma patients treated with frontline liver resection
- Author
-
Pelizzaro, F., primary, Trevisani, F., additional, Vitale, A., additional, Cillo, U., additional, Piscaglia, F., additional, Missale, G., additional, Sangiovanni, A., additional, Foschi, F.G., additional, Cabibbo, G., additional, Caturelli, E., additional, Di Marco, M., additional, Azzaroli, F., additional, Brunetto, M.R., additional, Raimondo, G., additional, Vidili, G., additional, Guarino, M., additional, Gasbarrini, A., additional, Campani, C., additional, Svegliati-Baroni, G., additional, Giannini, E.G., additional, Mega, A., additional, Masotto, A., additional, Rapaccini, G.L., additional, Magalotti, D., additional, Sacco, R., additional, Nardone, G., additional, and Farinati, F., additional
- Published
- 2023
- Full Text
- View/download PDF
11. Which is the best therapy for not transplantable patients with multinodular early HCC?
- Author
-
Vitale, A., primary, Romano, F., additional, Famularo, S., additional, Farinati, F., additional, Trevisani, F., additional, and Cillo, U., additional
- Published
- 2023
- Full Text
- View/download PDF
12. Lack of substantial improvements in the landscape of alcohol-related hepatocellular carcinoma in the last 15 years: The need to improve cancer prevention and surveillance
- Author
-
Reggidori, N., primary, Bucci, L., additional, Santi, V., additional, Stefanini, B., additional, Lani, L., additional, Rampoldi, D., additional, Caturelli, E., additional, Farinati, F., additional, Masotto, A., additional, Mega, A., additional, Biasini, E., additional, Foschi, F.G., additional, Svegliati-Baroni, G., additional, Sangiovanni, A., additional, Campani, C., additional, Raimondo, G., additional, Vidili, G., additional, Gasbarrini, A., additional, Celsa, C., additional, Di Marco, M., additional, Giannini, E.G., additional, Sacco, R., additional, Brunetto, M.R., additional, Azzaroli, F., additional, Magalotti, D., additional, Morisco, F., additional, Rapaccini, G.L., additional, Nardone, G., additional, Vitale, A., additional, and Trevisani, F., additional
- Published
- 2023
- Full Text
- View/download PDF
13. Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications
- Author
-
Vitale, A, Farinati, F, Finotti, M, Di Renzo, C, Brancaccio, G, Piscaglia, F, Cabibbo, G, Caturelli, E, Missale, G, Marra, F, Sacco, R, Giannini, E, Trevisani, F, Cillo, U, Bhoori, S, Borzio, M, Burra, P, Casadei Gardini, A, Carrai, P, Conti, F, Cozzolongo, R, Cucchetti, A, D'Ambrosio, R, Dell'Unto, C, De Matthaeis, N, Di Costanzo, G, Di Sandro, S, Famularo, S, Foschi, F, Fucilli, F, Galati, G, Gambato, M, Gasbarrini, A, Giuliante, F, Ghinolfi, D, Grieco, A, Gruttadauria, S, Guarino, M, Iavarone, M, Kostandini, A, Lai, Q, Lenci, I, Levi Sandri, G, Losito, F, Lupo, L, Marasco, G, Manzia, T, Mazzocato, S, Masarone, M, Melandro, F, Mescoli, C, Miele, L, Morisco, F, Muley, M, Nicolini, D, Pagano, D, Persico, M, Pompili, M, Ponziani, F, Pravisani, R, Rapaccini, G, Rendina, M, Renzulli, M, Romano, F, Rossi, M, Rreka, E, Russo, F, Sangiovanni, A, Sessa, A, Simonetti, N, Sposito, C, Tortora, R, Vigano, L, Vigano, M, Villa, E, Vincenzi, V, Violi, P, Azzaroli, F, Brunetto, M, Di Marco, A, Masotto, A, Mega, A, Nardone, G, Oliveri, F, Raimondo, G, Svegliati Baroni, G, Vidili, G, Zoli, M, Vitale A., Farinati F., Finotti M., Di Renzo C., Brancaccio G., Piscaglia F., Cabibbo G., Caturelli E., Missale G., Marra F., Sacco R., Giannini E. G., Trevisani F., Cillo U., Bhoori S., Borzio M., Burra P., Casadei Gardini A., Carrai P., Conti F., Cozzolongo R., Cucchetti A., D'ambrosio R., Dell'unto C., De Matthaeis N., Di Costanzo G. G., Di Sandro S., Famularo S., Foschi F. G., Fucilli F., Galati G., Gambato M., Gasbarrini A., Giuliante F., Ghinolfi D., Grieco A., Gruttadauria S., Guarino M., Iavarone M., Kostandini A., Lai Q., Lenci I., Levi Sandri G. V., Losito F., Lupo L. G., Marasco G., Manzia T. M., Mazzocato S., Masarone M., Melandro F., Mescoli C., Miele L., Morisco F., Muley M., Nicolini D., Pagano D., Persico M., Pompili M., Ponziani F. R., Pravisani R., Rapaccini G. L., Rendina M., Renzulli M., Romano F., Rossi M., Rreka E., Russo F. P., Sangiovanni A., Sessa A., Simonetti N., Sposito C., Tortora R., Vigano L., Vigano M., Villa E., Vincenzi V., Violi P., Azzaroli F., Brunetto M. R., Di Marco A., Masotto A., Mega A., Nardone G., Oliveri F., Raimondo G., Svegliati Baroni G., Vidili G., Zoli M., Vitale, A, Farinati, F, Finotti, M, Di Renzo, C, Brancaccio, G, Piscaglia, F, Cabibbo, G, Caturelli, E, Missale, G, Marra, F, Sacco, R, Giannini, E, Trevisani, F, Cillo, U, Bhoori, S, Borzio, M, Burra, P, Casadei Gardini, A, Carrai, P, Conti, F, Cozzolongo, R, Cucchetti, A, D'Ambrosio, R, Dell'Unto, C, De Matthaeis, N, Di Costanzo, G, Di Sandro, S, Famularo, S, Foschi, F, Fucilli, F, Galati, G, Gambato, M, Gasbarrini, A, Giuliante, F, Ghinolfi, D, Grieco, A, Gruttadauria, S, Guarino, M, Iavarone, M, Kostandini, A, Lai, Q, Lenci, I, Levi Sandri, G, Losito, F, Lupo, L, Marasco, G, Manzia, T, Mazzocato, S, Masarone, M, Melandro, F, Mescoli, C, Miele, L, Morisco, F, Muley, M, Nicolini, D, Pagano, D, Persico, M, Pompili, M, Ponziani, F, Pravisani, R, Rapaccini, G, Rendina, M, Renzulli, M, Romano, F, Rossi, M, Rreka, E, Russo, F, Sangiovanni, A, Sessa, A, Simonetti, N, Sposito, C, Tortora, R, Vigano, L, Vigano, M, Villa, E, Vincenzi, V, Violi, P, Azzaroli, F, Brunetto, M, Di Marco, A, Masotto, A, Mega, A, Nardone, G, Oliveri, F, Raimondo, G, Svegliati Baroni, G, Vidili, G, Zoli, M, Vitale A., Farinati F., Finotti M., Di Renzo C., Brancaccio G., Piscaglia F., Cabibbo G., Caturelli E., Missale G., Marra F., Sacco R., Giannini E. G., Trevisani F., Cillo U., Bhoori S., Borzio M., Burra P., Casadei Gardini A., Carrai P., Conti F., Cozzolongo R., Cucchetti A., D'ambrosio R., Dell'unto C., De Matthaeis N., Di Costanzo G. G., Di Sandro S., Famularo S., Foschi F. G., Fucilli F., Galati G., Gambato M., Gasbarrini A., Giuliante F., Ghinolfi D., Grieco A., Gruttadauria S., Guarino M., Iavarone M., Kostandini A., Lai Q., Lenci I., Levi Sandri G. V., Losito F., Lupo L. G., Marasco G., Manzia T. M., Mazzocato S., Masarone M., Melandro F., Mescoli C., Miele L., Morisco F., Muley M., Nicolini D., Pagano D., Persico M., Pompili M., Ponziani F. R., Pravisani R., Rapaccini G. L., Rendina M., Renzulli M., Romano F., Rossi M., Rreka E., Russo F. P., Sangiovanni A., Sessa A., Simonetti N., Sposito C., Tortora R., Vigano L., Vigano M., Villa E., Vincenzi V., Violi P., Azzaroli F., Brunetto M. R., Di Marco A., Masotto A., Mega A., Nardone G., Oliveri F., Raimondo G., Svegliati Baroni G., Vidili G., and Zoli M.
- Abstract
Prognostic assessment in patients with HCC remains an extremely difficult clinical task due to the complexity of this cancer where tumour characteristics interact with degree of liver dysfunction, patient general health status, and a large span of available treatment options. Several prognostic systems have been proposed in the last three decades, both from the Asian and European/North American countries. Prognostic scores, such as the CLIP score and the recent MESH score, have been generated on a solid statistical basis from real life population data, while staging systems, such as the BCLC scheme and the recent CNLC classification, have been created by experts according to recent HCC prognostic evidences from the literature. A third category includes combined prognostic systems that can be used both as prognostic scores and staging systems. A recent example is the ITA.LI.CA prognostic system including either a prognostic score and a simplified staging system. This review focuses first on an overview of the main prognostic systems for HCC classified according to the above three categories, and, second, on a comprehensive description of the methodology required for a correct comparison between different systems in terms of prognostic performance. In this second section the main studies in the literature comparing different prognostic systems are described in detail. Lastly, a formal comparison between the last prognostic systems proposed for each of the above three categories is performed using a large Italian database including 6882 HCC patients in order to concretely apply the comparison rules previously described.
- Published
- 2021
14. Pattern of macrovascular invasion in hepatocellular carcinoma
- Author
-
Guarino, M., Cucchetti, A., Pontillo, G., Farinati, F., Benevento, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Rodolfo, S., Cabibbo, G., Marra, F., Mega, A., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Giannini, E. G., Morisco, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Rampoldi, D., Santi, V., Forgione, A., Granito, A., Muratori, L., Piscaglia, F., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Pelizzaro, F., Imondi, A., Sartori, A., Penzo, B., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., Pieri, G., de Matthaeis, N., Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Olivari, A., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, F., Berardinelli, D., Ercolani, G., Napoli, L., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Capasso, M., Fiorentino, A., Pignata, L., Cossiga, V., Romagnoli, V., Guarino M., Cucchetti A., Pontillo G., Farinati F., Benevento F., Rapaccini G.L., Di Marco M., Caturelli E., Zoli M., Rodolfo S., Cabibbo G., Marra F., Mega A., Gasbarrini A., Svegliati-Baroni G., Foschi F.G., Missale G., Masotto A., Nardone G., Raimondo G., Azzaroli F., Vidili G., Oliveri F., Trevisani F., Giannini E.G., Morisco F., Biselli M., Caraceni P., Garuti F., Gramenzi A., Neri A., Rampoldi D., Santi V., Forgione A., Granito A., Muratori L., Piscaglia F., Sansone V., Tovoli F., Dajti E., Marasco G., Ravaioli F., Cappelli A., Golfieri R., Mosconi C., Renzulli M., Cela E.M., Facciorusso A., Pelizzaro F., Imondi A., Sartori A., Penzo B., Cacciato V., Casagrande E., Moscatelli A., Pellegatta G., Pieri G., de Matthaeis N., Allegrini G., Lauria V., Ghittoni G., Pelecca G., Chegai F., Coratella F., Ortenzi M., Olivari A., Inno A., Marchetti F., Busacca A., Camma C., Di Martino V., Rizzo G.E.M., Franze M.S., Saitta C., Sauchella A., Bevilacqua V., Borghi A., Gardini A.C., Conti F., Berardinelli D., Ercolani G., Napoli L., Campani C., Di Bonaventura C., Gitto S., Coccoli P., Malerba A., Capasso M., Fiorentino A., Pignata L., Cossiga V., Romagnoli V., Guarino, M., Cucchetti, A., Pontillo, G., Farinati, F., Benevento, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Rodolfo, S., Cabibbo, G., Marra, F., Mega, A., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Giannini, E. G., Morisco, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Rampoldi, D., Santi, V., Forgione, A., Granito, A., Muratori, L., Piscaglia, F., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Pelizzaro, F., Imondi, A., Sartori, A., Penzo, B., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., Pieri, G., de Matthaeis, N., Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Olivari, A., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, F., Berardinelli, D., Ercolani, G., Napoli, L., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Capasso, M., Fiorentino, A., Pignata, L., Cossiga, V., and Romagnoli, V.
- Subjects
Ablation Techniques ,Male ,Registrie ,Cirrhosis ,Clinical Biochemistry ,Mesenteric Vein ,loco-regional treatment ,030204 cardiovascular system & hematology ,Biochemistry ,Gastroenterology ,surgery ,Antineoplastic Agent ,Liver disease ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,cirrhosis ,hepatocellular carcinoma ,portal vein thrombosis ,transplantation ,Ascites ,Ablation Technique ,Registries ,030212 general & internal medicine ,Chronic ,Settore MED/12 - Gastroenterologia ,Portal Vein ,Liver Diseases ,Liver Neoplasms ,General Medicine ,Middle Aged ,Sorafenib ,Prognosis ,Hepatitis B ,Alcoholic ,Hepatitis C ,Tumor Burden ,Survival Rate ,Italy ,Liver Neoplasm ,Hepatocellular carcinoma ,Ascite ,Female ,medicine.symptom ,Liver cancer ,Human ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Prognosi ,Antineoplastic Agents ,End Stage Liver Disease ,03 medical and health sciences ,Mesenteric Veins ,Hepatitis B, Chronic ,Internal medicine ,medicine ,Humans ,Hepatectomy ,Neoplasm Invasiveness ,portal vein thrombosi ,Liver Diseases, Alcoholic ,Aged ,Neoplasm Invasivene ,Performance status ,business.industry ,Carcinoma ,Settore MED/09 - MEDICINA INTERNA ,Patient Acuity ,Hepatocellular ,Hepatitis C, Chronic ,medicine.disease ,Liver Transplantation ,Transplantation ,Liver function ,business ,cirrhosi - Abstract
Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed to evaluate interactions between MaVI, clinical variables and treatment, exploring the inter-relationship determining overall survival. Results: MaVI prevalence was 11.1%, and median survival of these patients was 6.0months (95% CI, 5.1-7.1). MaVI was associated with younger age at diagnosis, presence of symptoms, worse Performance Status (PS) and liver function, high alphafetoprotein levels and large HCCs. MaVI extension was associated with worse PS, ascites and greater impairment in liver function. RPA identified patients' categories with different treatment indications and survival, ranging from 2.4months in those with PS>1 and ascites, regardless of MaVI extension (receiving best supportive care in 90.3% of cases), to 14.1months in patients with PS 0-1, no ascites and Vp1-Vp2 MaVI (treated with surgery in 19.1% of cases). Conclusions: MaVI presence and extension, together with PS and ascites, significantly affect patients' survival and treatment selection. The decision tree based on these parameters may help assess patients' prognosis and inform therapeutic decisions.
- Published
- 2021
- Full Text
- View/download PDF
15. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study
- Author
-
Marasco, G, Colecchia, A, Bacchi Reggiani ML, Celsa, C, Farinati, F, Giannini, Eg, Benevento, F, Rapaccini, Gl, Caturelli, E, Di Marco, M, Biasini, E, Marra, F, Morisco, F, Foschi, Fg, Zoli, M, Gasbarrini, A, Baroni, Gs, Masotto, A, Sacco, R, Raimondo, G, Azzaroli, F, Mega, A, Vidili, G, Brunetto, Mr, Nardone, G, Dajti, E, Ravaioli, F, Avanzato, F, Festi, D, Trevisani, F, group, Italian Liver Cancer (ITA. LI. CA., Marasco G., Colecchia A., Bacchi Reggiani M.L., Celsa C., Farinati F., Giannini E.G., Benevento F., Rapaccini G.L., Caturelli E., Di Marco M., Biasini E., Marra F., Morisco F., Foschi F.G., Zoli M., Gasbarrini A., Baroni G.S., Masotto A., Sacco R., Raimondo G., Azzaroli F., Mega A., Vidili G., Brunetto M.R., Nardone G., Dajti E., Ravaioli F., Avanzato F., Festi D., Trevisani F., Marasco, G., Colecchia, A., Bacchi Reggiani, M. L., Celsa, C., Farinati, F., Giannini, E. G., Benevento, F., Rapaccini, G. L., Caturelli, E., Di Marco, M., Biasini, E., Marra, F., Morisco, F., Foschi, F. G., Zoli, M., Gasbarrini, A., Baroni, G. S., Masotto, A., Sacco, R., Raimondo, G., Azzaroli, F., Mega, A., Vidili, G., Brunetto, M. R., Nardone, G., Dajti, E., Ravaioli, F., Avanzato, F., Festi, D., and Trevisani, F.
- Subjects
Oncology ,Male ,Survival ,Hepatocellular carcinoma ,Cohort study, Hepatocellular carcinoma, Prognosis, Sorafenib, Survival ,Severity of Illness Index ,Antineoplastic Agent ,0302 clinical medicine ,Prospective Studies ,Liver Neoplasms ,Gastroenterology ,Middle Aged ,Sorafenib ,Prognosis ,Treatment Outcome ,Italy ,Liver Neoplasm ,030220 oncology & carcinogenesis ,Cohort ,030211 gastroenterology & hepatology ,Female ,Liver cancer ,Cohort study ,medicine.drug ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Prognosi ,Settore MED/12 - GASTROENTEROLOGIA ,Antineoplastic Agents ,Risk Assessment ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,neoplasms ,Prognostic models ,Neoplasm Staging ,Proportional Hazards Models ,Retrospective Studies ,Hepatology ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Gold standard ,medicine.disease ,digestive system diseases ,Multicenter study ,business - Abstract
Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p
- Published
- 2021
16. Polyclonal and monoclonal B lymphocytes response in HCV‐infected patients treated with direct‐acting antiviral agents
- Author
-
Schiavinato, A., Zanetto, A., Pantano, G., Tosato, F., Nabergoj, M., Fogar, P., Piva, E., Gambato, M., Franceschet, E., Floreani, A., Farinati, F., Burra, P., Russo, F. P., and Plebani, M.
- Published
- 2017
- Full Text
- View/download PDF
17. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon
- Author
-
Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E. G., Tovoli, F., Ciccarese, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Virdone, R., Marra, F., Felder, M., Morisco, F., Benvegnù, L., Gasbarrini, A., Svegliati‐Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Nardone, G., Colecchia, A., Persico, M., Boccaccio, V., Craxì, A., Bruno, S., Trevisani, F., Cammà, C., Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Piscaglia, Fabio, Gramenzi, Annagiulia, Granito, Alessandro, Magalotti, Donatella, Serra, Carla, Negrini, Giulia, Napoli, L., Napoli, Lucia, Salvatore, Veronica, Benevento, Francesca, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Poggio, Paolo Del, Olmi, Stefano, de Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, DellʼIsola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Rini, Francesca, Costantino, Andrea, Affronti, Andrea, Affronti, Marco, Mascari, Marta, Mega, Andrea, Pompili, Maurizio, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Missale, Gabriele, Guarino, Maria, Ortolani, Alessio, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Aburas, Sami, Inghilesi, Andrea L., Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Coccoli, Piero, and Zamparelli, Marco Sanduzzi
- Published
- 2017
- Full Text
- View/download PDF
18. OC.07.3 AUTOIMMUNE ATROPHIC GASTRITIS: DIFFERENCES BETWEEN HELICOBACTER PYLORI ASSOCIATED AND NON-ASSOCIATED DISEASE
- Author
-
Pilotto, V., primary, Zingone, F., additional, Gobitti, G., additional, Fassan, M., additional, Pennelli, G., additional, Cardin, R., additional, Marsilio, I., additional, and Farinati, F., additional
- Published
- 2022
- Full Text
- View/download PDF
19. T.08.6 CIRCULATING MICRORNA-21 AND HIF-1ALPHA IN CHRONIC LIVER DISEASES AND HEPATOCELLULAR CARCINOMA
- Author
-
Pelizzaro, F., primary, Cardin, R., additional, Russo, F.P., additional, Penzo, B., additional, Pinto, E., additional, Kitenge, M.P., additional, Bertellini, F., additional, Palano, G., additional, and Farinati, F., additional
- Published
- 2022
- Full Text
- View/download PDF
20. OC.07.6 THE ROLE OF HELICOBACTER PYLORI IN AUTOIMMUNE ATROPHIC GASTRITIS: DISEASE PHENOTYPE AND MIRNA EXPRESSION
- Author
-
Pilotto, V., primary, Cardin, R., additional, Zingone, F., additional, Marsilio, I., additional, Maddalo, G., additional, Orlando, C., additional, and Farinati, F., additional
- Published
- 2022
- Full Text
- View/download PDF
21. Correction to: Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion (Journal of Neurology, (2022), 269, 10, (5606-5614), 10.1007/s00415-022-11269-7)
- Author
-
Garri, F., Russo, F. P., Carrer, T., Weis, L., Pistonesi, F., Mainardi, M., Sandre, M., Savarino, E., Farinati, F., Del Sorbo, F., Soliveri, P., Calandrella, D., Biundo, R., Carecchio, M., Zecchinelli, A. L., Pezzoli, G., and Antonini, A.
- Published
- 2022
22. Cysteine and Serine Proteases in Duodenal Ulcer
- Author
-
Herszényi, L., Farinati, F., Plebani, M., Carraro, P., De Paoli, M., Di Mario, F., Kusstatscher, S., Naccarato, R., Tulassay, Z., Mózsik, Gy., editor, Nagy, L., editor, Pár, A., editor, and Rainsford, K. D., editor
- Published
- 1997
- Full Text
- View/download PDF
23. The Role of Cysteine and Serine Proteases in Gastric Carcinogenesis and Their Prognostic Impact in Gastric Cancer
- Author
-
Herszényi, L., Farinati, F., Plebani, M., Carraro, P., De Paoli, M., Roveroni, G., Naccarato, R., Tulassay, Z., Mózsik, Gy., editor, Nagy, L., editor, Pár, A., editor, and Rainsford, K. D., editor
- Published
- 1997
- Full Text
- View/download PDF
24. Zinc and Digestive Diseases
- Author
-
Sturniolo, G. C., D’Inca, R., Mestriner, C., Irato, P., Di Leo, V., D’Odorico, A., Venturi, C., Longo, G., Farinati, F., Nève, Jean, editor, Chappuis, Philippe, editor, and Lamand, Michel, editor
- Published
- 1996
- Full Text
- View/download PDF
25. Letter: is female sex really associated with better prognosis in hepatocellular carcinoma?
- Author
-
Pelizzaro, F., Penzo, B., Trevisani, F., Farinati, F., Pelizzaro F., Penzo B., Trevisani F., and Farinati F.
- Subjects
Carcinoma, Hepatocellular ,Prognosi ,Carcinoma ,Liver Neoplasms ,Humans ,Hepatectomy ,Hepatocellular ,Female ,Prognosis ,Human - Abstract
Lettera
- Published
- 2021
26. Increased platelet aggregation in decompensated cirrhosis indicates higher risks of further decompensation and liver-related mortality
- Author
-
Zanetto, A., primary, Campello, E., additional, Bulato, C., additional, Gavasso, S., additional, Shalaby, S., additional, Gambato, M., additional, Germani, G., additional, Farinati, F., additional, Russo, F.P., additional, Burra, P., additional, Simioni, P., additional, and Senzolo, M., additional
- Published
- 2022
- Full Text
- View/download PDF
27. Transarterial chemoembolization for hepatocellular carcinoma in clinical practice: temporal trends and survival outcomes over the last three decades in Italy
- Author
-
Pelizzaro, F., primary, Haxhi, S., additional, Penzo, B., additional, Palano, G., additional, Pinto, E., additional, Bertellini, F., additional, Vitale, A., additional, Giannini, E.G., additional, Trevisani, F., additional, and Farinati, F., additional
- Published
- 2022
- Full Text
- View/download PDF
28. Years of life that could be saved from prevention of hepatocellular carcinoma
- Author
-
Cucchetti, A., Trevisani, F., Bucci, L., Ravaioli, M., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, A., Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Pinna, A. D., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, DellʼIsola, Serena, Lalungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo
- Published
- 2016
- Full Text
- View/download PDF
29. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome
- Author
-
Bucci, L., Garuti, F., Camelli, V., Lenzi, B., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, A., Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Trevisani, F., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Capelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Roselli, Paola, Isola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pelagatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Cammà, Calogero, Cabibbo, Giuseppe, Costantino, Andrea, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Porro, Emanuela, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo
- Published
- 2016
- Full Text
- View/download PDF
30. Activation by Human Gastric Mucosa of Alimentary Procarcinogens
- Author
-
Cardin, R., Zordan, M., Farinati, F., Naccarato, R., Levis, A. G., and Palmer, T. Norman, editor
- Published
- 1991
- Full Text
- View/download PDF
31. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective?
- Author
-
Farinati, F and Gianni, S
- Published
- 2001
32. Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer Patients
- Author
-
Vitale, A., Saracino, E., Boccagni, P., Brolese, A., D'Amico, F., Gringeri, E., Neri, D., Srsen, N., Valmasoni, M., Zanus, G., Carraro, A., Violi, P., Pauletto, A., Bassi, D., Polacco, M., Burra, P., Farinati, F., Feltracco, P., Romano, A., D'Amico, D.F., and Cillo, U.
- Published
- 2009
- Full Text
- View/download PDF
33. OC.04.6 CIRCULATING PROSTAGLANDIN E2: A NOVEL POTENTIAL PROGNOSTIC BIOMARKER IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
- Author
-
Pelizzaro, F., primary, Kitenge, M.P., additional, Cardin, R., additional, Penzo, B., additional, Ponzoni, A., additional, Cillo, U., additional, Vitale, A., additional, Businello, G., additional, Munari, G., additional, Fassan, M., additional, and Farinati, F., additional
- Published
- 2021
- Full Text
- View/download PDF
34. OC.08.5 EFFECTIVENESS OF EMPIRICAL SECOND-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
- Author
-
Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Francis, M., additional, O”Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional
- Published
- 2021
- Full Text
- View/download PDF
35. OC.04.1 HIGH LEVELS OF TRANSAMINASES AT ADMISSION PREDICT A SEVERE DISEASE COURSE IN COVID-19 HOSPITALIZED PATIENTS
- Author
-
Pelizzaro, F., primary, Kitenge, M.P., additional, Maran, F., additional, Cocconcelli, E., additional, Balestro, E., additional, Spagnolo, P., additional, Cattelan, A., additional, and Farinati, F., additional
- Published
- 2021
- Full Text
- View/download PDF
36. OC.08.4 ANTIBIOTIC RESISTANCE TRENDS OF ITALIAN H. PYLORI NAÏVE PATIENTS BETWEEN 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
- Author
-
Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Francis, M., additional, O”Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional
- Published
- 2021
- Full Text
- View/download PDF
37. AF.79 EPIDEMIOLOGICAL TRENDS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH METABOLIC-DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN ITALY
- Author
-
Cucco, M., primary, Vitale, A., additional, Svegliati–Baroni, G., additional, Marchesini, G., additional, Cillo, U., additional, Trevisani, F., additional, Miele, L., additional, and Farinati, F., additional
- Published
- 2021
- Full Text
- View/download PDF
38. OC.04.5 IMPACT OF HOSPITAL VOLUME ON HEPATOCELLULAR CARCINOMA SURVIVAL IN ITALY
- Author
-
Penzo, B., primary, Pelizzaro, F., additional, Imondi, A., additional, Sartori, A., additional, Vitale, A., additional, Trevisani, F., additional, and Farinati, F., additional
- Published
- 2021
- Full Text
- View/download PDF
39. OC.05.1 IDENTIFICATION OF MARKERS OF OXIDATIVE STRESS IN CELIAC DISEASE
- Author
-
Marsilio, I., primary, Cardin, R., additional, Maniero, D., additional, Lorenzon, G., additional, Scaramuzza, G., additional, Savarino, E.V., additional, Farinati, F., additional, and Zingone, F., additional
- Published
- 2021
- Full Text
- View/download PDF
40. AF.24 CHARACTERISTICS OF EMPIRICAL FIRST- AND SECOND-LINE TREATMENT BETWEEN 2013-2020: ITALIAN DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
- Author
-
Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Mégraud, F., additional, O’Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional
- Published
- 2021
- Full Text
- View/download PDF
41. OC.04.10 PROGNOSTIC ROLE OF PLATELETS-TO-LYMPHOCYTES RATIO (PLR) AND NEUTROPHILS-TO-LYMPHOCYTES RATIO (NLR) IN HEPATOCELLULAR CARCINOMA PATIENTS
- Author
-
Penzo, B., primary, Pelizzaro, F., additional, Sartori, A., additional, Imondi, A., additional, Vitale, A., additional, Trevisani, F., additional, and Farinati, F., additional
- Published
- 2021
- Full Text
- View/download PDF
42. OC.08.2 EFFECTIVENESS OF EMPIRICAL FIRST-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
- Author
-
Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Mégraud, F., additional, O”Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional
- Published
- 2021
- Full Text
- View/download PDF
43. Pattern of macrovascular invasion in hepatocellular carcinoma
- Author
-
Guarino, Mariateresa, Cucchetti, A., Pontillo, G., Farinati, F., Benevento, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Rodolfo, S., Cabibbo, G., Marra, F., Mega, A., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Giannini, E. G., Morisco, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Rampoldi, D., Santi, V., Forgione, Alessandra, Granito, A., Muratori, L., Piscaglia, F., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Pelizzaro, F., Imondi, A., Sartori, A., Penzo, B., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., Pieri, G., De Matthaeis, Nicoletta, Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Olivari, Elena Armida, Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, Francesco, Berardinelli, D., Ercolani, G., Napoli, L., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Capasso, Monica, Fiorentino, Alice, Pignata, L., Cossiga, V., Romagnoli, V., Guarino M., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), Forgione A., de Matthaeis N., Olivari A., Conti F., Capasso M., Fiorentino A., Guarino, Mariateresa, Cucchetti, A., Pontillo, G., Farinati, F., Benevento, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Rodolfo, S., Cabibbo, G., Marra, F., Mega, A., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Giannini, E. G., Morisco, F., Biselli, M., Caraceni, P., Garuti, F., Gramenzi, A., Neri, A., Rampoldi, D., Santi, V., Forgione, Alessandra, Granito, A., Muratori, L., Piscaglia, F., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Pelizzaro, F., Imondi, A., Sartori, A., Penzo, B., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., Pieri, G., De Matthaeis, Nicoletta, Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Olivari, Elena Armida, Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Borghi, A., Gardini, A. C., Conti, Francesco, Berardinelli, D., Ercolani, G., Napoli, L., Campani, C., Di Bonaventura, C., Gitto, S., Coccoli, P., Malerba, A., Capasso, Monica, Fiorentino, Alice, Pignata, L., Cossiga, V., Romagnoli, V., Guarino M., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), Forgione A., de Matthaeis N., Olivari A., Conti F., Capasso M., and Fiorentino A.
- Abstract
Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed to evaluate interactions between MaVI, clinical variables and treatment, exploring the inter-relationship determining overall survival. Results: MaVI prevalence was 11.1%, and median survival of these patients was 6.0 months (95% CI, 5.1-7.1). MaVI was associated with younger age at diagnosis, presence of symptoms, worse Performance Status (PS) and liver function, high alphafetoprotein levels and large HCCs. MaVI extension was associated with worse PS, ascites and greater impairment in liver function. RPA identified patients' categories with different treatment indications and survival, ranging from 2.4 months in those with PS > 1 and ascites, regardless of MaVI extension (receiving best supportive care in 90.3% of cases), to 14.1 months in patients with PS 0-1, no ascites and Vp1-Vp2 MaVI (treated with surgery in 19.1% of cases). Conclusions: MaVI presence and extension, together with PS and ascites, significantly affect patients' survival and treatment selection. The decision tree based on these parameters may help assess patients' prognosis and inform therapeutic decisions.
- Published
- 2021
44. The changing scenario of hepatocellular carcinoma in Italy: an update
- Author
-
Garuti, F., Neri, A., Avanzato, F., Gramenzi, A., Rampoldi, D., Rucci, P., Farinati, F., Giannini, E. G., Piscaglia, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Brunetto, M. R., Trevisani, F., Biselli, M., Caraceni, P., Santi, V., Granito, A., Muratori, L., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., De Matthaeis, Nicoletta, Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Biasini, E., Olivani, A., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Berardinelli, D., Borghi, A., Gardini, A. C., Conti, Francesco, Cucchetti, A., Dall'Aglio, A. C., Ercolani, G., Campani, C., Di Bonaventura, C., Gitto, S., Malerba, P. C. A., Capasso, Monica, Guarino, Mariateresa, Oliveri, F., Romagnoli, V., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), de Matthaeis N., Conti F., Capasso M., Guarino M., Garuti, F., Neri, A., Avanzato, F., Gramenzi, A., Rampoldi, D., Rucci, P., Farinati, F., Giannini, E. G., Piscaglia, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Brunetto, M. R., Trevisani, F., Biselli, M., Caraceni, P., Santi, V., Granito, A., Muratori, L., Sansone, V., Tovoli, F., Dajti, E., Marasco, G., Ravaioli, F., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Cela, E. M., Facciorusso, A., Cacciato, V., Casagrande, E., Moscatelli, A., Pellegatta, G., De Matthaeis, Nicoletta, Allegrini, G., Lauria, V., Ghittoni, G., Pelecca, G., Chegai, F., Coratella, F., Ortenzi, M., Biasini, E., Olivani, A., Inno, A., Marchetti, F., Busacca, A., Camma, C., Di Martino, V., Rizzo, G. E. M., Franze, M. S., Saitta, C., Sauchella, A., Bevilacqua, V., Berardinelli, D., Borghi, A., Gardini, A. C., Conti, Francesco, Cucchetti, A., Dall'Aglio, A. C., Ercolani, G., Campani, C., Di Bonaventura, C., Gitto, S., Malerba, P. C. A., Capasso, Monica, Guarino, Mariateresa, Oliveri, F., Romagnoli, V., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), de Matthaeis N., Conti F., Capasso M., and Guarino M.
- Abstract
Background and aims: Epidemiology of hepatocellular carcinoma (HCC) is changing in most areas of the world. This study aimed at updating the changing scenario of aetiology, clinical presentation, management and prognosis of HCC in Italy during the last 15 years. Methods: Retrospective analysis of the Italian Liver Cancer (ITA.LI.CA) database included 6034 HCC patients managed in 23 centres from 2004 to 2018. Patients were divided into three groups according to the date of cancer diagnosis (2004-2008, 2009-2013 and 2014-2018). Results: The main results were: (i) a progressive patient ageing; (ii) a progressive increase of non-viral cases and, particularly, of ‘metabolic’ and ‘metabolic + alcohol’ HCCs; (iii) a slightly decline of cases diagnosed under surveillance, but with an incremental use of the semiannual schedule; (iv) a favourable cancer stage migration; (v) an increased use of radiofrequency ablation to the detriment of percutaneous ethanol injection; (vi) improved outcomes of ablative and transarterial treatments; (vii) an improved overall survival (adjusted for the lead time in surveyed patients) in the last calendar period, particularly in viral patients; (viii) a large gap between the number of potential candidates (according to oncologic criteria and age) to liver transplant and that of transplanted patients. Conclusions: During the last 15 years several aspects of HCC scenario have changed, as well as its management. The improvement in patient survival observed in the last period was likely because of a larger use of thermal ablation with respect to the less effective alcohol injection and to an improved management of intermediate stage patients.
- Published
- 2021
45. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter
- Author
-
Carr, B. I., Guerra, V., Donghia, R., Farinati, F., Giannini, E. G., Piscaglia, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), Carr, B. I., Guerra, V., Donghia, R., Farinati, F., Giannini, E. G., Piscaglia, F., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., and Gasbarrini A. (ORCID:0000-0002-7278-4823)
- Abstract
Background: Hepatocellular carcinoma prognosis depends on both liver and tumor determinants, especially on maximum tumor diameter, multifocality, and presence of portal vein thrombosis, despite apparently complete tumor removal by resection or liver transplantation. Aims: To examine parameters of hepatocellular carcinoma aggressiveness as tumor size increases. Methods: A large hepatocellular carcinoma database was examined for trends in serum alpha-fetoprotein and the percentage of patients with macroscopic portal vein thrombosis or tumor multifocality. Results: A total of 13,016 hepatocellular carcinoma patients were identified having full tumor and survival data. Of these, 76.56% were male and 23.44% were female, with a median age of 64.4 years. We found that as the maximum tumor diameter increased, there was a significant trend for increased alpha-fetoprotein levels (P<0.001) and an increased percentage of patients with either portal vein thrombosis or tumor multifocality, each P<0.0001. Furthermore, the increases of both alpha-fetoprotein and portal vein thrombosis were proportionately greater than the related maximum tumor diameter increases. These trends of increased alpha-fetoprotein, portal vein thrombosis, and multifocality with increasing maximum tumor diameter had non-linear patterns. Within alpha-fetoprotein and multifocality trends, there were identifiable sub-trends associated with specific maximum tumor diameter ranges. Conclusions: The greater fold-increases in alpha-fetoprotein and portal vein thrombosis compared with increases in maximum tumor diameter imply that hepatocellular carcinoma characteristics may change with increasing size to a more aggressive phenotype, suggesting that follow-up tumor sampling might be useful, in addition to baseline tumor sampling, for optimal therapeutic choices to be made.
- Published
- 2021
46. Identification of clinical phenotypes and related survival in patients with large hccs
- Author
-
Carr, B. I., Guerra, V., Donghia, R., Farinati, F., Giannini, E. G., Muratori, L., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Sacco, R., Celsa, C., Campani, C., Mega, A., Guarino, M., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F. G., Biasini, E., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Brunetto, M. R., Trevisani, F., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Guarino M., Gasbarrini A. (ORCID:0000-0002-7278-4823), Carr, B. I., Guerra, V., Donghia, R., Farinati, F., Giannini, E. G., Muratori, L., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Sacco, R., Celsa, C., Campani, C., Mega, A., Guarino, M., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F. G., Biasini, E., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Brunetto, M. R., Trevisani, F., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Guarino M., and Gasbarrini A. (ORCID:0000-0002-7278-4823)
- Abstract
Background. Hepatocellular carcinoma (HCC) factors, especially maximum tumor diameter (MTD), tumor multifocality, portal vein thrombosis (PVT), and serum alpha-fetoprotein (AFP), influence survival. Aim. To examine patterns of tumor factors in large HCC patients. Methods. A database of large HCC patients was examined. Results. A multiple Cox proportional hazard model on death identified low serum albumin levels and the presence of PVT and multifocality, with each having a hazard ratio ≥2.0. All combinations of these three parameters were examined in relation to survival. Using univariate Cox analysis, the combination of albumin >3.5 g/dL and the absence of both PVT and multifocality had the best survival rate, while all combinations that included the presence of PVT had poor survival and hazard ratios. We identified four clinical phenotypes, each with a distinct median survival: patients with or without PVT or multifocality plus serum albumin ≥3.5 (g/dL), with each subgroup displaying high (≥100 IU/mL) or low (<100 IU/mL) blood AFP levels. Across a range of MTDs, we identified only two significant trends, blood AFP and platelets. Conclusions. Patients with large HCCs have distinct phenotypes and survival, as identified by the combination of PVT, multifocality, and blood albumin levels.
- Published
- 2021
47. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study
- Author
-
Marasco, G., Colecchia, A., Bacchi Reggiani, M. L., Celsa, C., Farinati, F., Giannini, E. G., Benevento, F., Rapaccini, Gian Ludovico, Caturelli, E., Di Marco, Maria Teresa, Biasini, E., Marra, F., Morisco, F., Foschi, F. G., Zoli, M., Gasbarrini, Antonio, Baroni, G. S., Masotto, A., Sacco, R., Raimondo, G., Azzaroli, F., Mega, A., Vidili, G., Brunetto, M. R., Nardone, G., Dajti, E., Ravaioli, F., Avanzato, F., Festi, D., Trevisani, F., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), Marasco, G., Colecchia, A., Bacchi Reggiani, M. L., Celsa, C., Farinati, F., Giannini, E. G., Benevento, F., Rapaccini, Gian Ludovico, Caturelli, E., Di Marco, Maria Teresa, Biasini, E., Marra, F., Morisco, F., Foschi, F. G., Zoli, M., Gasbarrini, Antonio, Baroni, G. S., Masotto, A., Sacco, R., Raimondo, G., Azzaroli, F., Mega, A., Vidili, G., Brunetto, M. R., Nardone, G., Dajti, E., Ravaioli, F., Avanzato, F., Festi, D., Trevisani, F., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., and Gasbarrini A. (ORCID:0000-0002-7278-4823)
- Abstract
Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p<0.001) at univariate analysis, except the Albumin-Bilirubin score. The Italian Liver Cancer score (CLIP) yielded the highest accuracy (C-index 0.604, AIC 9898), followed by the ITA.LI.CA. prognostic score (C-index 0.599, AIC 9915). Conclusions: The CLIP score had the highest accuracy in predicting the overall survival of HCC patients treated with Sorafenib, although its performance remained poor. Further studies are needed to refine the current ability to predict the outcome of HCC patients undergoing Sorafenib.
- Published
- 2021
48. Monofocal hepatocellular carcinoma: How much does size matter?
- Author
-
Pelizzaro, F., Penzo, B., Peserico, G., Imondi, A., Sartori, A., Vitale, A., Cillo, U., Giannini, E. G., Forgione, A., Ludovico Rapaccini, G., Di Marco, M., Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, A., Svegliati-Baroni, G., Giuseppe Foschi, F., Olivani, A., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Farinati, F., Vitale A., Forgione A., Di Marco M., Gasbarrini A. (ORCID:0000-0002-7278-4823), Pelizzaro, F., Penzo, B., Peserico, G., Imondi, A., Sartori, A., Vitale, A., Cillo, U., Giannini, E. G., Forgione, A., Ludovico Rapaccini, G., Di Marco, M., Caturelli, E., Zoli, M., Sacco, R., Cabibbo, G., Marra, F., Mega, A., Morisco, F., Gasbarrini, A., Svegliati-Baroni, G., Giuseppe Foschi, F., Olivani, A., Masotto, A., Nardone, G., Raimondo, G., Azzaroli, F., Vidili, G., Oliveri, F., Trevisani, F., Farinati, F., Vitale A., Forgione A., Di Marco M., and Gasbarrini A. (ORCID:0000-0002-7278-4823)
- Abstract
BACKGROUND & AIMS: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, monofocal hepatocellular carcinoma (HCC) is classified as early (BCLC A) irrespective of its size, even though controversies still exist regarding staging and treatment of large tumours. We aimed at evaluating the appropriate staging and treatment for large (>5 cm) monofocal (HCC). METHODS: From the Italian Liver Cancer database, we selected 924 patients with small early monofocal HCC (2-5 cm; SEM-HCC), 163 patients with larger tumours (>5 cm; LEM-HCC) and 1048 intermediate stage patients (BCLC B). RESULTS: LEM-HCC patients had a worse overall survival (OS) than SEM-HCC (31.0 vs 49.0 months; P < .0001), and this was confirmed at multivariate analysis (HR 1.63, 95% CI 1.29-2.05; P < .0001). The small difference in OS between LEM-HCC and BCLC B patients (31.0 vs 27.0 months; P = .03) disappeared in the multivariate model (HR 0.98, 95% CI 0.77-1.25; P = .89). In all monofocal tumours, treatment was the strongest independent predictor of survival, with a progressively decreasing survival benefit moving from "curative" to "palliative" therapies. The survival of resected patients with LEM-HCC was significantly shorter than that of SEM-HCC (44.0 vs 78.0 months; P = .002), but liver resection provided the highest survival benefit in both groups compared to other treatments. CONCLUSIONS: Monofocal HCC larger than 5 cm should not be staged as BCLC A and either a different staging system or a different subgrouping of patients (e.g. BCLC AB) should be used. Liver resection, if feasible, remains the recommended treatment for all these patients.
- Published
- 2021
49. Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients
- Author
-
Pelizzaro, F., Vitale, Antonio, Sartori, A., Vieno, A., Penzo, B., Russo, F. P., Frigo, A. C., Giannini, E. G., Piccinnu, M., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Sacco, R., Celsa, C., Marra, F., Mega, A., Guarino, Mariateresa, Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Coccoli, P., Raimondo, G., Azzaroli, F., Vidili, G., Brunetto, M. R., Trevisani, F., Farinati, F., Vitale A., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Guarino M., Gasbarrini A. (ORCID:0000-0002-7278-4823), Pelizzaro, F., Vitale, Antonio, Sartori, A., Vieno, A., Penzo, B., Russo, F. P., Frigo, A. C., Giannini, E. G., Piccinnu, M., Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, E., Zoli, M., Sacco, R., Celsa, C., Marra, F., Mega, A., Guarino, Mariateresa, Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Coccoli, P., Raimondo, G., Azzaroli, F., Vidili, G., Brunetto, M. R., Trevisani, F., Farinati, F., Vitale A., Rapaccini G. L. (ORCID:0000-0002-6467-857X), Di Marco M., Guarino M., and Gasbarrini A. (ORCID:0000-0002-7278-4823)
- Abstract
Purpose: We aimed at assessing the impact of surveillance on long-term survival in HCC patients. Methods: From the ITA.LI.CA database, we selected 1028 cases with long (≥5 years, LS group) and 2721 controls with short-term survival (<5 years, SS group). The association between surveillance and LS was adjusted for confounders by multivariable logistic regression analysis. Survival of surveilled patients was presented both as observed and corrected for the lead-time bias, and the comparison of survival between surveillance and no surveillance groups was also performed after balancing the baseline characteristics with inverse probability weights (IPW). Results: LS patients were more frequently diagnosed under surveillance (p < 0.0001), and had more favorable baseline characteristics. Surveillance was an independent predictor of LS (OR = 1.413, 95% CI 1.195– 1.671; p < 0.0001). The observed and the lead-time corrected survival of surveilled patients were significantly longer compared to the survival of not surveilled patients (p < 0.0001 and p = 0.0008, respectively). In IPW adjusted populations, no survival differences were demonstrated between the two groups (p = 0.30). Conclusions: Surveillance, increasing early-stage diagnosis and applicability of curative treatments, is a fundamental determinant of long-term survival in HCC patients. A wide implementation of surveillance programs should be pursued in order to improve HCC patients’ prognosis.
- Published
- 2021
50. Consensus statement on diet and gastric cancer
- Author
-
Berglund, G, Hill, M J, Caygill, C P J, Farinati, F, Giacosa, A, De Koster, E, Reed, P I, Sobrinho-Simoes, M, and Stockbrugger, R
- Published
- 1997
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.